drugset / Trial / NCT06874725
Latent Tuberculosis in Type 2 Diabetes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.
Timeline
- Start
- 2018-04-18
- Primary completion
- 2024-04-30
- Completion
- 2025-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Isoniazid | Small molecule | — | — |
| Comparator | Rifapentine | Small molecule | — | — |